Open Label, Dose Escalation Phase I Study of AZD2281
The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies
Advanced Solid Malignancies
DRUG: KU-0059436 (AZD2281)(PARP inhibitor)
The primary objective of this study is to determine the safety and tolerability of AZD2281., assessed after each visit
The secondary objectives of the study are to determine MTD and pharmacokinetic profile of oral AZD2281., assessed after each visit
The purpose of the study is to assess the safety and tolerability of AZD2281 following single and multiple oral doses in patients in Japan with advanced solid malignancies